naa a22 4500 510763324 CHVBK 20180411083147.0 cr unu---uuuuu 180411e20130901xx s 000 0 eng 10.1007/s12094-012-0993-x doi (NATIONALLICENCE)springer-10.1007/s12094-012-0993-x Panitumumab and irinotecan every 3weeks is an active and convenient regimen for second-line treatment of patients with wild-type K-RAS metastatic colorectal cancer [Elektronische Daten] [A. Carrato, A. Gómez, P. Escudero, M. Chaves, F. Rivera, E. Marcuello, E. González, C. Grávalos, M. Constenla, J. Manzano, F. Losa, J. Maurel, R. Dueñas, B. Massuti, J. Gallego, J. Aparicio, A. Antón, E. Aranda] Purpose: To evaluate the efficacy and safety profile of the combination of panitumumab and irinotecan every 3weeks in a phase II trial as second-line treatment in patients with advanced wild-type (WT) K-RAS colorectal cancer (CRC). Methods: Fifty-three patients received 9mg/kg of panitumumab followed by 350mg/m2 of irinotecan every 21days until disease progression, unacceptable toxicity or consent withdrawal. Results: Median age of patients included was 67years. All patients had previously received 5-fluorouracil, 84% oxaliplatin and 8% irinotecan as first-line treatment. Patients received a median of five infusions of panitumumab and irinotecan. On an intention-to-treat analysis, 12 patients (23%) achieved partial responses and 22 patients (41%) achieved disease stabilization. Median progression-free survival and overall survival were 4.5 and 15.1months, respectively. The most frequent treatment-related severe toxicities per patient were diarrhoea (35.8%), followed by skin rash (32.1%), asthenia (18.9%) and neutropenia (13.2%). A significant association between clinical response and incidence and grade of skin toxicity was observed (p=0.0032). Conclusion: This study shows that the administration of panitumumab plus irinotecan every 3weeks is safe, active and feasible as second-line treatment in patients with advanced WT K-RAS CRC. Federación de Sociedades Españolas de Oncología (FESEO), 2012 Colorectal cancer nationallicence Epidermal growth factor receptor (EGFR) inhibitors nationallicence Monoclonal antibodies nationallicence Prospective trial nationallicence Topoisomerase I inhibitors nationallicence Carrato A. Medical Oncology Department, Ramón y Cajal University Hospital, Ctra. Colmenar Viejo Km. 9,1, 28034, Madrid, Spain aut Gómez A. Medical Oncology Department, Reina Sofía Hospital, Córdoba, Spain aut Escudero P. Medical Oncology Department, Clínico Lozano Blesa University Hospital, Zaragoza, Spain aut Chaves M. Medical Oncology Department, Virgen del Rocío University Hospital, Sevilla, Spain aut Rivera F. Medical Oncology Department, Marqués de Valdecilla University Hospital, Santander, Spain aut Marcuello E. Medical Oncology Department, Santa Creu i Sant Pau Hospital, Barcelona, Spain aut González E. Medical Oncology Department, Virgen de las Nieves Hospital, Granada, Spain aut Grávalos C. Medical Oncology Department, Doce de Octubre University Hospital, Madrid, Spain aut Constenla M. Medical Oncology Department, Pontevedra Hospital Complex, Pontevedra, Spain aut Manzano J. Medical Oncology Department, Catalán Oncology Institut, German Trias I Pujol Hospital, Badalona, Spain aut Losa F. Medical Oncology Department, L′Hospitalet General Hospital, Barcelona, Spain aut Maurel J. Medical Oncology Department, Clínic Hospital, Barcelona, Spain aut Dueñas R. Medical Oncology Department, Jaén Hospital Complex, Jaen, Spain aut Massuti B. Medical Oncology Department, Alicante General Hospital, Alicante, Spain aut Gallego J. Medical Oncology Department, Elche University General Hospital, Elche, Spain aut Aparicio J. Medical Oncology Department, La Fe University Hospital, Valencia, Spain aut Antón A. Medical Oncology Department, Miguel Servet Hospital, Zaragoza, Spain aut Aranda E. Medical Oncology Department, Reina Sofía Hospital, Córdoba, Spain aut Clinical and Translational Oncology Springer Milan 15/9(2013-09-01), 705-711 1699-048X 15:9<705 2013 15 12094 https://doi.org/10.1007/s12094-012-0993-x text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s12094-012-0993-x text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Carrato A. Medical Oncology Department, Ramón y Cajal University Hospital, Ctra. Colmenar Viejo Km. 9,1, 28034, Madrid, Spain aut NATIONALLICENCE 700 1- Gómez A. Medical Oncology Department, Reina Sofía Hospital, Córdoba, Spain aut NATIONALLICENCE 700 1- Escudero P. Medical Oncology Department, Clínico Lozano Blesa University Hospital, Zaragoza, Spain aut NATIONALLICENCE 700 1- Chaves M. Medical Oncology Department, Virgen del Rocío University Hospital, Sevilla, Spain aut NATIONALLICENCE 700 1- Rivera F. Medical Oncology Department, Marqués de Valdecilla University Hospital, Santander, Spain aut NATIONALLICENCE 700 1- Marcuello E. Medical Oncology Department, Santa Creu i Sant Pau Hospital, Barcelona, Spain aut NATIONALLICENCE 700 1- González E. Medical Oncology Department, Virgen de las Nieves Hospital, Granada, Spain aut NATIONALLICENCE 700 1- Grávalos C. Medical Oncology Department, Doce de Octubre University Hospital, Madrid, Spain aut NATIONALLICENCE 700 1- Constenla M. Medical Oncology Department, Pontevedra Hospital Complex, Pontevedra, Spain aut NATIONALLICENCE 700 1- Manzano J. Medical Oncology Department, Catalán Oncology Institut, German Trias I Pujol Hospital, Badalona, Spain aut NATIONALLICENCE 700 1- Losa F. Medical Oncology Department, L′Hospitalet General Hospital, Barcelona, Spain aut NATIONALLICENCE 700 1- Maurel J. Medical Oncology Department, Clínic Hospital, Barcelona, Spain aut NATIONALLICENCE 700 1- Dueñas R. Medical Oncology Department, Jaén Hospital Complex, Jaen, Spain aut NATIONALLICENCE 700 1- Massuti B. Medical Oncology Department, Alicante General Hospital, Alicante, Spain aut NATIONALLICENCE 700 1- Gallego J. Medical Oncology Department, Elche University General Hospital, Elche, Spain aut NATIONALLICENCE 700 1- Aparicio J. Medical Oncology Department, La Fe University Hospital, Valencia, Spain aut NATIONALLICENCE 700 1- Antón A. Medical Oncology Department, Miguel Servet Hospital, Zaragoza, Spain aut NATIONALLICENCE 700 1- Aranda E. Medical Oncology Department, Reina Sofía Hospital, Córdoba, Spain aut NATIONALLICENCE 773 0- Clinical and Translational Oncology Springer Milan 15/9(2013-09-01), 705-711 1699-048X 15:9<705 2013 15 12094 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer